Financial Performance - Revenues for the three months ended October 31, 2025, were approximately $9.7 million, a decrease from $12.1 million for the same period in 2024, while revenues for the nine months ended October 31, 2025, were approximately $31.2 million compared to $31.8 million in 2024[88]. - Operating income for the three months ended October 31, 2025, was approximately $774,000, down from $1.9 million in the same period of 2024, and for the nine months ended October 31, 2025, it was approximately $2.8 million compared to $4.0 million in 2024[88]. - Gross profit margin for the three months ended October 31, 2025, increased to 47% from 45% in the same period of 2024, and for the nine months, it remained at 47% compared to 45% in 2024[90]. - The company anticipates generating net income for fiscal 2026, following positive Adjusted EBITDA for fiscal 2024 and fiscal 2025[97]. Order Backlog and Future Expectations - As of October 31, 2025, the backlog of firm orders was approximately $7.2 million, down from $16.9 million as of January 31, 2025, but additional orders totaling approximately $9.5 million were received after this date[79]. - The company expects revenue in the fourth quarter of fiscal 2026 to improve compared to the third quarter of fiscal 2026, driven by increased activity and backlog[80]. - The company is pursuing new product initiatives and significant project opportunities that could positively impact future financial results, particularly in fiscal 2027[80]. Cash Flow and Capital - For the nine months ended October 31, 2025, the company generated net cash provided by operating activities of approximately $5.9 million, compared to cash used in operating activities of approximately $1.4 million for the same period in 2024[99][104]. - As of October 31, 2025, the company had working capital of approximately $36.0 million, including cash and cash equivalents of approximately $19.4 million, an increase from working capital of approximately $23.5 million and cash equivalents of approximately $5.3 million as of January 31, 2025[98][103]. - The company raised approximately $10.8 million in new capital through the sale of common stock, significantly increasing liquidity[82]. - Net cash provided by financing activities for the nine months ended October 31, 2025, was approximately $10.8 million, primarily from sales of common stock under the ATM program[106]. - The company initiated an at-the-market (ATM) offering program in September 2025, allowing for gross proceeds of up to $25.0 million, and has generated net proceeds of approximately $10.8 million from the issuance of approximately 1.0 million shares of common stock[100]. Expenses and Investments - Research and development costs for the three and nine months ended October 31, 2025, were approximately $506,000 and $1.2 million, respectively, compared to $562,000 and $1.4 million in the same periods of 2024[92]. - General and administrative expenses for the three and nine months ended October 31, 2025, were approximately $3.0 million and $10.0 million, respectively, compared to $2.8 million and $8.3 million in 2024, primarily due to higher stock-based compensation[91]. - The company’s facility in Huntsville, Texas underwent an expansion, which is expected to lead to increased revenue following the resumption of repair and production operations[78]. Tax and Foreign Operations - The income tax expense for the three months ended October 31, 2025, was approximately $716,000 on pre-tax income of approximately $778,000, compared to an income tax expense of approximately $396,000 on pre-tax income of approximately $1.7 million for the same period in 2024[95]. - As of October 31, 2025, the company had deposits in foreign banks totaling approximately $4.9 million, which could be distributed to the United States without adverse tax consequences[108]. - The company has determined that undistributed earnings of foreign subsidiaries are not deemed indefinitely reinvested outside of the United States as of October 31, 2025[107]. - The company does not currently hold or issue foreign exchange contracts or other derivative instruments to hedge currency exposure, which includes approximately $566,000 in cash and cash equivalents denominated in foreign currencies[113]. - The company has no off-balance sheet arrangements as of October 31, 2025[109].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42938 Evommune, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 85-0742575 (State or other jurisdiction ...

For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Exzeo Group, Inc. (Exact Name of Registrant as Specified in its Charter) Florida 85-2578837 (State or other jurisdiction of incorporation or organization ...

Financial Performance - Revenue for Q2 FY 2026 was approximately $17.1 million, a 24% increase compared to $15.8 million in Q2 FY 2025[3] - Operating income for Q2 FY 2026 was $1.7 million, down from $2.6 million in Q2 FY 2025[3] - Net income for Q2 FY 2026 was $1.8 million or $0.18 per diluted share, compared to $2.7 million or $0.28 per diluted share in Q2 FY 2025[3] - Cash provided by operating activities for the first six months of FY 2026 was approximately $0.6 million, down from $2.4 million in the same period of FY 2025[3] - The company reported a gross margin of $6.5 million for Q2 FY 2026, compared to $7.6 million in Q2 FY 2025[14] Backlog and Contracts - The backlog as of October 31, 2025, was approximately $82 million, up from $70 million at April 30, 2025[3] - The company anticipates multiple large contract awards in the coming months, contributing to growth in core technologies[5] Growth Opportunities - The company is pursuing growth opportunities in quantum sensing and alternative position, navigation, and timing solutions, expected to expand markets over the next 3 to 5 years[5] - The second annual Quantum Sensing Summit is rescheduled for January 14-15, 2026, to discuss emerging technologies and strategies[6] Assets - Total assets as of October 31, 2025, were approximately $92.3 million, a decrease from $93.7 million at April 30, 2025[16]

Financial Performance - Consolidated net sales for Q1 fiscal 2026 were $111.0 million, a decrease of 4.1% from $115.8 million in Q1 fiscal 2025[214][225]. - Gross margin improved to 33.1% in Q1 fiscal 2026, up from 12.5% in Q1 fiscal 2025, reflecting cost reduction actions and improved product mix[214]. - GAAP net loss attributable to common stockholders was $19.8 million, with a GAAP EPS net loss of $0.67 and Non-GAAP EPS net loss of $0.18[214]. - New bookings totaled $101.9 million, resulting in a book-to-bill ratio of 0.92x for the quarter[214]. - Backlog as of October 31, 2025, was $663.0 million, down from $811.0 million a year earlier[214]. - Gross profit for the three months ended October 31, 2025, was $36.8 million, an increase of $22.3 million or 153.3% compared to $14.5 million in the same period of 2024, with gross profit as a percentage of consolidated net sales rising from 12.5% to 33.1%[230]. - The operating loss for the three months ended October 31, 2025, was $2.8 million, significantly improved from an operating loss of $129.2 million in the prior year period[249]. - For the three months ended October 31, 2025, the consolidated net loss attributable to common stockholders was $19.8 million, a significant improvement from a net loss of $155.9 million in the prior year period[263]. Segment Performance - The Satellite and Space Communications segment net sales were $55.1 million, a decrease of 6.5% from $58.9 million in Q1 fiscal 2025[226]. - The Allerium segment net sales were $55.9 million, a decrease of 1.8% from $56.9 million in Q1 fiscal 2025[227]. - The Satellite and Space Communications segment reported an operating loss of $11.4 million for the three months ended October 31, 2025, compared to an operating loss of $118.8 million in the same period of 2024[249]. - The Allerium segment achieved an operating income of $5.4 million for the three months ended October 31, 2025, compared to $5.3 million in 2024[249]. - The Satellite and Space Communications segment reported an operating income of $3.2 million for the three months ended October 31, 2025, compared to an operating loss of $118.8 million in the same period last year[265]. Cash Flow and Liquidity - Cash flows from operating activities were $8.1 million, marking the third consecutive quarter of positive operating cash flows[215]. - Cash and cash equivalents increased to $43.6 million as of October 31, 2025, up from $40.0 million on July 31, 2025[273]. - Net cash provided by operating activities was $8.1 million for the three months ended October 31, 2025, compared to a net cash used of $21.8 million in the prior year period, reflecting a significant improvement[273]. - Net cash used in investing activities was $3.3 million for the three months ended October 31, 2025, primarily for capital expenditures in the Allerium segment[276]. - Total outstanding borrowings under the Credit Facility were $135.0 million as of October 31, 2025, with $17.6 million drawn on the Revolver Loan[282]. - Available sources of liquidity totaled $51.0 million as of October 31, 2025, including cash and cash equivalents of $41.4 million[282]. Costs and Expenses - Consolidated selling, general and administrative expenses decreased to $29.9 million for the three months ended October 31, 2025, down from $51.6 million in 2024, representing 27.0% of consolidated net sales compared to 44.6% in the prior year[235]. - Research and development expenses increased slightly to $3.8 million for the three months ended October 31, 2025, from $3.7 million in 2024, representing 3.4% of consolidated net sales compared to 3.2%[240]. - The company incurred $2.4 million in restructuring costs during the three months ended October 31, 2025, compared to $6.5 million in the same period of 2024[237]. - Unallocated expenses decreased to $9.0 million in the recent period from $9.5 million in the prior year, primarily due to lower overall expenditures for selling, general, and administrative expenses[254]. Strategic Outlook - The company anticipates long-term growth in end markets due to increasing demand for global voice, video, and data usage, as well as the growth of emergency communication networks[193]. - The company is exploring strategic alternatives for its businesses, which may impact future results of operations[228]. - The company plans to continue focusing on research and development, despite higher expenses in this area, to drive future growth and innovation[266]. - The company expects recurring annualized cost savings of approximately $3.0 million from migrating production capabilities to Chandler, Arizona[217]. - The company may raise additional funds through equity and debt financing to provide flexibility or pursue acquisitions[280]. Risks and Challenges - The company faces risks related to the integration of acquired businesses and the successful implementation of strategic activities, which may not yield expected benefits[192]. - The company’s contracts with the U.S. government can be terminated for convenience at any time, leading to unpredictable funding and deployment[195]. - Significant fluctuations in sales and operating results are expected due to factors such as short-term or long-term contracts and changes in estimated fair value of derivative instruments[195]. - The company provides warranty coverage for most products for at least one year from the date of shipment, with liabilities recorded based on historical claims and product failure rates[203].

Revenue Performance - Net revenue increased by 7% to $2.6 billion, with comparable sales rising by 1% or 2% on a constant dollar basis[98] - Net revenue for the third quarter of 2025 was $1,733,382, a decrease of 2.1% compared to $1,770,382 in 2024, primarily due to a 5% decrease in comparable sales[120] - Year-to-date net revenue for the first three quarters of 2025 was $7,461,799, a 7% increase from $6,976,629 in 2024, with significant contributions from China Mainland and Rest of World[130] - Total net revenue increased by 7% in the third quarter of 2025 compared to the same period in 2024, with a notable 46% increase in the China Mainland market[158] - Net revenue in the Americas segment increased by $32,078 to $5,166,157, a growth of 0.6% year-over-year[137] - In China Mainland, net revenue surged by $290,048 to $1,226,361, representing a 31.0% increase compared to $936,313 in 2024[140] - The Rest of World segment reported a net revenue increase of $163,044, reaching $1,069,281, an 18.0% growth year-over-year[142] Profitability and Expenses - Income from operations decreased by 11% to $435.9 million, resulting in an operating margin decline of 350 basis points to 17.0%[108] - Gross profit increased by 2% to $1.4 billion, but gross margin decreased by 290 basis points to 55.6%[98] - Selling, general and administrative expenses rose by 8.6% to $988.3 million, accounting for 38.5% of net revenue[113] - Net income for the third quarter of 2025 was $306,835, a decrease of 12.8% from $351,870 in 2024, primarily due to increased selling, general and administrative expenses[129] - Gross profit in the Americas segment decreased to $981,861, down 10.2% from $1,092,921 in the previous year, attributed to lower product margins and higher occupancy costs[120] - Selling, general and administrative expenses rose to $2,882,783, reflecting an increase of $258,571 or 9.9% from $2,624,212 in 2024[132] - Other income decreased by 57.4% to $5,854, primarily due to lower interest income from decreased cash balances and interest rates[127] Market Performance - Americas comparable sales decreased by 5%, while China Mainland comparable sales increased by 24% or 25% on a constant dollar basis[98] - The increase in net revenue was primarily driven by growth in China Mainland and Rest of World, partially offset by a decline in the Americas[112] - Comparable sales in China Mainland increased by 16%, driven by higher e-commerce traffic[140] - Comparable sales in the Americas decreased by 5% in the third quarter of 2025, while China Mainland saw a 24% increase[158] Tax and Corporate Expenses - The effective tax rate increased to 30.5% in 2025 from 30.2% in 2024, primarily due to adjustments upon the filing of income tax returns[128] - The effective tax rate increased to 30.4%, up 60 basis points from 29.8% in 2024[146] - Corporate expenses decreased by $4.1 million to $339.6 million, mainly due to lower employee costs and decreased incentive compensation[126] - Corporate expenses rose to $1.0 billion, an increase of $61.5 million compared to the previous year, primarily due to higher technology and marketing costs[144] Cash Flow and Liquidity - Cash provided by operating activities was $459.6 million in the first three quarters of 2025, a decrease of $411.7 million compared to $871.3 million in 2024[162] - As of November 2, 2025, the company's cash and cash equivalents totaled $1.035 billion, with working capital excluding cash at $1.046 billion[167] - The company believes its liquidity resources will be adequate to meet capital expenditure requirements for at least the next 12 months[166] - As of November 2, 2025, the company held cash and cash equivalents of $1.0 billion[184] - The committed revolving credit facility provides available borrowings up to $600.0 million, with no outstanding borrowings other than letters of credit and guarantees of $7.0 million as of November 2, 2025[183] Inventory and Operations - The inventory balance increased by 11% to $2.0 billion as of November 2, 2025, compared to October 27, 2024[169] - The company operated 796 stores globally as of November 2, 2025, an increase from 767 stores in February 2025[174] - The company repurchased 3.5 million shares at a total cost of $906.6 million in the first three quarters of 2025, down from 4.2 million shares costing $1.3 billion in the same period of 2024[165] Economic Factors - Increased tariffs and the removal of the de minimis exemption are expected to reduce income from operations by approximately $210 million for 2025[105] - Foreign currency fluctuations negatively impacted net revenue growth by $15.4 million compared to the first three quarters of 2024[109] - The company experienced a $15.4 million decrease in revenue due to fluctuations in foreign currency exchange rates in the first three quarters of 2025 compared to the same period in 2024[177] - Inflationary pressures, including higher product, transportation, labor, and raw material costs, may adversely affect operating results if not offset through pricing or efficiencies[186]

Exhibit 99.1 LULULEMON ATHLETICA INC. ANNOUNCES THIRD QUARTER FISCAL 2025 RESULTS BOARD OF DIRECTORS AUTHORIZES $1.0 BILLION INCREASE IN ITS STOCK REPURCHASE PROGRAM Revenue increased 7% to $2.6 billion Comparable sales increased 1%, or 2% on a constant dollar basis Diluted EPS of $2.59 Vancouver, British Columbia – December 11, 2025 – lululemon athletica inc. (NASDAQ:LULU) today announced financial results for the third quarter of fiscal 2025, which ended on November 2, 2025. Calvin McDonald, Chief Executi ...

Table of Contents FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the quarterly period ended November 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-35992 Oracle Corporation (Exact name of registrant as specified in its charter) (State or o ...

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized to deliver on key milestones following completion of initial public offering (IPO), raising $172.5 million in gross proceeds, including the full exercise of the underwriters' option to purchase additional shares Palo Alto, Calif., December 11, 2025 – Evo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia, Canada 47-1099599 (State ...